Hims & Hers Expands Globally and Secures Financing, but Core Margin Pressure Persists

What happened

Hims & Hers Health continues its strategic pivot from compounded to branded GLP-1s, completing the Eucalyptus acquisition to add 850,000 customers and $450 million in ARR across international markets, while securing a $400 million receivables facility from JPMorgan to support growth without equity dilution. However, the company's first quarter following the pivot revealed deep operational strain: revenue grew just 4% year-over-year to $608.1 million, gross margin collapsed 800 basis points to 65%, adjusted EBITDA halved to $44.3 million, and net income swung to a $92.1 million loss. Monthly revenue per subscriber declined from $85 to $80, indicating that new obesity subscribers are diluting monetization even as total subscribers rose 9% to 2.584 million. FDA staff challenged seven compounded peptides, eliminating the high-margin fallback and reinforcing the need for Hims to prove branded weight-loss economics can work. Despite the positive news around international scale and financing, the core challenge remains: converting obesity demand into profitable, sticky subscribers at scale.

Implication

Hims is building a global platform with improved financial flexibility, but the bull case now rests entirely on proving that branded GLP-1 subscriptions can restore gross margins toward 70% and EBITDA margins toward 10%-12% in the second half of 2026. Without clear retention and cohort economics, the stock's 51x EV/EBITDA multiple offers no margin of safety.

Thesis delta

The thesis remains a 'show me' story: the international expansion and financing reduce capital risk, but they do not address the fundamental question of whether Hims can profitably intermediate branded weight-loss drugs. The margin trajectory from Q1 2026 must inflect sharply in Q2 and Q3—if it doesn't, the stock's premium valuation will prove unsustainable.